Market open
LAVA Therapeutics/$LVTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LAVA Therapeutics
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
Ticker
$LVTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
34
ISIN
NL0015000AG6
Website
LVTX Metrics
BasicAdvanced
$33M
-
-$1.05
-
-
Price and volume
Market cap
$33M
52-week high
$1.51
52-week low
$1.03
Average daily volume
51K
Financial strength
Current ratio
6.732
Quick ratio
6.421
Long term debt to equity
0.023
Total debt to equity
1.21
Interest coverage (TTM)
-60.98%
Management effectiveness
Return on assets (TTM)
-23.02%
Return on equity (TTM)
-73.21%
Valuation
Price to revenue (TTM)
6.836
Price to book
1.32
Price to tangible book (TTM)
1.32
Growth
Revenue change (TTM)
-60.20%
Earnings per share change (TTM)
-1.79%
3-year revenue growth (CAGR)
-2.43%
3-year earnings per share growth (CAGR)
-5.97%
LVTX News
AllArticlesVideos
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
GlobeNewsWire·1 day ago
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
GlobeNewsWire·4 weeks ago
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for LAVA Therapeutics stock?
LAVA Therapeutics (LVTX) has a market cap of $33M as of May 15, 2025.
What is the P/E ratio for LAVA Therapeutics stock?
The price to earnings (P/E) ratio for LAVA Therapeutics (LVTX) stock is 0 as of May 15, 2025.
Does LAVA Therapeutics stock pay dividends?
No, LAVA Therapeutics (LVTX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next LAVA Therapeutics dividend payment date?
LAVA Therapeutics (LVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for LAVA Therapeutics?
LAVA Therapeutics (LVTX) does not currently have a Beta indicator.